Pathological magnetic resonance imaging findings in myelin oligodendrocyte glycoprotein antibody-associated disease
Authors:
M. Vaněčková 1; P. Nytrová 2
Authors place of work:
Oddělení MR, Radiodiagnostická klinika 1. LF UK a VFN v Praze
1; Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN v Praze
2
Published in the journal:
Cesk Slov Neurol N 2022; 85(4): 330-335
Category:
Z klinické praxe
doi:
https://doi.org/10.48095/cccsnn2022330
Summary
Myelin oligodendrocyte glycoprotein antibody-associated disease is a recently identified autoimmune demyelinating disease that occurs both in adults and children. Clinical symptoms of this disease may overlap with MS or neuromyelitis optica spectrum disorders clinical presentation. In addition to the presence of serum autoantibodies, MRI findings in the brain and spinal cord are important for the diagnosis of the disease. Articles have been published describing pathological findings on MRI in an attempt to define the typical pattern of involvement for this disease and to distinguish it from other demyelinating diseases. Some patients were diagnosed under other medical conditions in the past. We would like to share our experience with MRI diagnosis of this disease and present the findings of a cohort of seven patients.
Keywords:
MRI – Brain – Multiple sclerosis – Spinal cord – neuromyelitis optica – myelin oligodendrocyte glycoprotein
Zdroje
1. Marignier R, Hacohen Y, Cobo-Calvo A et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 2021; 20 (9): 762–772. doi: 10.1016/S1474-4422 (21) 00218-0.
2. Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody disease. J Neurol 2019; 266 (5): 1280–1286. doi: 10.1007/s00415-018-9122-2.
3. Deneve M, Biotti D, Patsoura S et al. MRI features of demyelinating disease associated with anti-MOG antibodies in adults, J Neuroradiol 2019; 46 (5): 312–318. doi: 10.1016/j.neurad.2019.06.001.
4. de Mol CL, Wong Y, van Pelt ED et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler 2020; 26 (7): 806–814. doi: 10.1177/1352458519845112.
5. Jarius S, Paul F, Aktas O et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 2018; 15 (1): 134. doi: 10.1186/s12974-018-1144-2.
6. Nytrová N. Historie neuromyelitis optica a onemocnění jejího širšího spektra, vývoj diagnostických kritérií. Cesk Slov Neurol N 2020; 83/116 (Suppl 1): 5–10. doi: 10.14735/amcsnn2020S5.
7. Ambrosius W, Michalak S, Kozubski W et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management. Int J Mol Sci 2020; 22 (1): 100. doi: 10.3390/ijms22010100.
8. Solomon JM, Paul F, Chien C et al. A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course. Ther Adv Neurol Disord 2021; 14: 17562864211014389. doi: 10.1177/17562864211014389.
9. Libertinova J. Epidemiologie, klinický obraz a průběh onemocnění u neuromyelitis optica a onemocnění jejího širšího spektra. Cesk Slov Neurol N 2020; 83/116 (Suppl 1): 15–19. doi: 10.14735/amcsnn2020S15.
10. Jurynczyk M, Messina S, Woodhall MR et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 2017; 140 (12): 3128–3138. doi: 10.1093/brain/awx276.
11. Wingerchuk DM, Lennon VA, Pittock SJ et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66 (10): 1485–1489. doi: 10.1212/01.wnl.0000216139.44259.74.
12. Salama S, Khan M, Shanechi A et al. MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler 2020; 26 (14): 1854–1865. doi: 10.1177/1352458 519893093.
13. Salama S, Khan M, Levy M et al. Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease. Mult Scler Relat Disord 2019; 29: 15–22. doi: 10.1016/j.msard.2019.01.021.
14. Jarius S, Ruprecht K, Kleiter I et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease aktivity, long-term course, association with AQP4-IgG and origin. J Neuroinflammation 2016; 13 (1): 279. doi: 10.1186/s12974-016-0717-1.
15. Ikeda A, Watanabe Y, Kaba H et al. MRI findings in pediatric neuromyelitis optica spectrum disorder with MOG antibody: Four cases and review of the literature. Brain Dev 2019; 41 (4): 367–372. doi: 10.1016/j.braindev.2018.10.011.
16. Vaněčková M. Nálezy na magnetické rezonanci u neuromyelitis optica a onemocnění jejího širšího spektra. Cesk Slov Neurol N 2020; 83/116 (Suppl 1): 20–30. doi: 10.14735/amcsnn2020S20.
17. Sechi E, Krecke KN, Messina SA et al. Comparison of MRI lesion evolution in different central nervous system demyelinating disorders. Neurology 2021; 97 (11): e1097–e1109. doi: 10.1212/WNL.0000000000012 467.
18. Dutra BG, Rocha AJ, Nunes RH et al. Neuromyelitis optica spectrum disorders: spectrum of MR imaging findings and their differential diagnosis. Radiographics 2018; 38 (1): 169–193. doi: 10.1148/rg.2018170 141.
19. Cobo-Calvo A, Ruiz A, Maillart E et al. Clinical spectrum and prognostic value of CNS MOG autoimunity in adults: the MOGADOR study. Neurology 2018; 90 (21): e1858–e1869. doi: 10.1212/WNL.0000000000005 560.
20. Budhram A, Mirian A, Le C et al. Unilateral cortical FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. J Neurol 2019; 266 (10): 2481–2487. doi: 10.1007/s00415-019-09440-8.
Štítky
Dětská neurologie Neurochirurgie NeurologieČlánek vyšel v časopise
Česká a slovenská neurologie a neurochirurgie
2022 Číslo 4
Nejčtenější v tomto čísle
- Validace dotazníku pro hodnocení dopadu cévní mozkové příhody – česká verze Stroke Impact Scale 3.0
- Telemedicínské vyšetření kognitivními testy ALBA, POBAV a ACE-III
- Patologické nálezy na zobrazení pomocí magnetické rezonance u onemocnění asociovaného s pozitivními protilátkami proti myelinovému oligodendrocytárnímu glykoproteinu
- Farmakogenetika dabigatranu a sekundární prevence ischemické cévní mozkové příhody